CELLECTIS news, videos and press releases
For more news please use our advanced search feature.
CELLECTIS - More news...
CELLECTIS - More news...
- Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
- Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
- Monthly information on share capital and company voting rights
- Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
- Monthly information on share capital and company voting rights
- Monthly information on share capital and company voting rights
- Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
- Monthly information on share capital and company voting rights
- Monthly information on share capital and company voting rights
- Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
- Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
- Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
- Monthly information on share capital and company voting rights
- Monthly information on share capital and company voting rights
- Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
- Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
- Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
- Cellectis Provides Financial Results for the Second Quarter 2024
- Monthly information on share capital and company voting rights
- FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
- FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
- Monthly information on share capital and company voting rights
- Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
- Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
- Monthly information on share capital and company voting rights
- Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
- Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
- Cellectis Reports Financial Results for First Quarter 2024
